Safety of Incretin-Based Therapies Hotly Debated Safety of Incretin-Based Therapies Hotly Debated
Should clinicians worry about possible cancer risks with incretin mimetic drugs for type 2 diabetes? Yes, say some experts. No, says another, arguing that substantial evidence is lacking. Medscape Medical News
Source: Medscape Cardiology Headlines - Category: Cardiology Tags: Diabetes & Endocrinology News Source Type: news
More News: Cancer | Cancer & Oncology | Cardiology | Diabetes | Diabetes Type 2 | Endocrinology | Heart | Incretin Therapy